BioPharma reports there are five “key trends currently shaping drug pricing decision” in the U.S.
Included among those trends are:
State and federal legislators have begun seriously targeting drug prices amid a growing bipartisan agreement that costs have become “unreasonable,” according to BioPharma.
New pricing models can also help tackle rising drug costs. The goal, BioPharma reports, is to develop models which are “more streamlined and yet flexible,” among other things.
“Right now, it’s kind of a complicated system of list prices and net prices and rebates, and it can lead to a lot of uncertainty and frustration for our patients,” PhRMA Public Affairs Deputy Vice President Holly Campbell says. “Our reimbursement system needs to better evolve to recognize and reward value. Not all patients are alike, and they all don’t benefit equally from each medicine, and we need to make sure that our payment system for medicines reflects those differences.”